
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - Successful use of anesthesia in pediatric patients requires more than a working knowledge of anesthetics, according to Gail de Imus, M.D.